Table
2: Baseline demographics.
|
Chemotherapy |
Total |
p-value |
||||||
|
R-CHOP (n = 24) |
non R-CHOP (n = 11) |
|||||||
|
n |
% |
n |
% |
n |
% |
|||
|
Sex |
Female |
7 |
29.2 |
3 |
27.3 |
10 |
28.6 |
1 |
|
Male |
17 |
70.8 |
8 |
72.7 |
25 |
71.4 |
||
|
Race |
African
American |
2 |
8.3 |
1 |
9.1 |
3 |
8.6 |
1 |
|
Asian |
1 |
4.2 |
0 |
0 |
1 |
2.9 |
||
|
White |
21 |
87.5 |
10 |
90.9 |
31 |
88.6 |
||
|
ECOG
PS |
0 |
7 |
29.2 |
1 |
9.1 |
8 |
22.9 |
0.22 |
|
1 |
10 |
41.7 |
5 |
45.5 |
15 |
42.9 |
||
|
2 |
6 |
25 |
2 |
18.2 |
8 |
22.9 |
||
|
Unknown |
1 |
4.2 |
3 |
27.3 |
4 |
11.4 |
||
|
Stage |
I |
2 |
8.3 |
2 |
18.2 |
4 |
11.4 |
0.32 |
|
II |
5 |
20.8 |
0 |
0 |
5 |
14.3 |
||
|
III |
5 |
20.8 |
4 |
36.4 |
9 |
25.7 |
||
|
IV |
12 |
50 |
5 |
45.5 |
17 |
48.6 |
||
|
aaIPI |
1 |
9 |
37.5 |
2 |
18.2 |
11 |
31.4 |
0.27 |
|
2 |
8 |
33.3 |
3 |
27.3 |
11 |
31.4 |
||
|
3 |
6 |
25 |
3 |
27.3 |
9 |
25.7 |
||
|
NA |
1 |
4.2 |
3 |
27.3 |
4 |
11.4 |
||
|
DLBCL
subtype |
GCB |
2 |
8.3 |
3 |
27.3 |
5 |
14.3 |
0.19 |
|
NOS |
15 |
62.5 |
7 |
63.6 |
22 |
62.9 |
||
|
Non-GCB |
7 |
29.2 |
1 |
9.1 |
8 |
22.9 |
||
|
Baseline
EF |
<
50% |
8 |
33.3 |
11 |
100 |
19 |
54.3 |
<
0.001 |
|
≥
50% |
16 |
66.7 |
0 |
0 |
16 |
45.7 |
||
|
Systolic
dysfunction |
No |
15 |
62.5 |
0 |
0 |
15 |
42.9 |
<
0.001 |
|
Yes |
7 |
29.2 |
10 |
90.9 |
17 |
48.6 |
||
|
Unknown |
2 |
8.3 |
1 |
9.1 |
3 |
8.6 |
||
|
Diastolic
dysfunction |
No |
1 |
4.2 |
3 |
27.3 |
4 |
11.4 |
0.004 |
|
Yes |
15 |
62.5 |
1 |
9.1 |
16 |
45.7 |
||
|
Unknown |
8 |
33.3 |
7 |
63.6 |
15 |
42.9 |
||
GCB:
Germinal Center B cell; NOS: Not Otherwise Specified; ABC: Aactivated B Cell =
non-GCB (according to WHO classification 2016).